3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Respiratory Tract Diseases
1
Neoplasms
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Pemetrexed
13
Carboplatin
13
Docetaxel
11
Cisplatin
11
pembrolizumab
9
Paclitaxel
8
Gemcitabine
7
Erlotinib Hydrochloride
4
Bevacizumab
4
anlotinib
3
Radiotherapy
3
Magnetic Resonance Spectroscopy
3
Gefitinib
3
Dexamethasone
3
dexamethasone acetate
2
dexamethasone 21-phosphate
2
cobimetinib
2
cemiplimab
2
auricularum
2
atezolizumab
2
apatinib
2
Vemurafenib
2
Surgical Procedures, Operative
2
Standard of Care
2
Specimen Handling
2
Ramucirumab
2
Calcium Dobesilate
2
trametinib
1
toripalimab
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Carcinoma, Non-Small-Cell Lung
×
AZD3759
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled